TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12854696

Group type: EXPERIMENTAL
Intervention: Cleaning intervention in uncarpeted homes
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cleaning intervention in carpeted homes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Correlation analysis for uncarpeted homes
Number of subjects: 39

Group type: COMPARATOR
Intervention: Correlation analysis for carpeted homes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Multiple regression model including confounding variables
Number of subjects: 39
Study: 10369553

Group type: EXPERIMENTAL
Intervention: Zemaphyte (traditional Chinese herbal medicine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8899317

Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 10
Study: 1930859

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF) 90 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 10
Study: 3911962

Group type: EXPERIMENTAL
Intervention: Suprofen suppositories
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paracetamol suppositories
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study: 29953986

Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard monitoring including pulse oximetry (Control)
Number of subjects: 185
Study: 26992096

Group type: EXPERIMENTAL
Intervention: Irbesartan (ARB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diltiazem (CCB)
Number of subjects: 60
Study: 25509939

Group type: EXPERIMENTAL
Intervention: Symptomatic TB infected females
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Symptomatic TB infected females on ATT
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control females
Number of subjects: 67
Study: 24397109

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (GCSF); dosage and duration not specified.
Number of subjects: 0
Study: 21564441

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 36
Study: 18492831

Group type: EXPERIMENTAL
Intervention: 50:50 glucose:fructose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25:75 glucose:fructose
Number of subjects: 6

Group type: COMPARATOR
Intervention: 100:0 glucose
Number of subjects: 6
Study: 16804018

Group type: EXPERIMENTAL
Intervention: Fermented papaya preparation 9 g/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 12654667

Group type: EXPERIMENTAL
Intervention: 1263W94 (50 to 1,600 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1263W94 (100 to 1,600 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1263W94
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 30
Study: 10767192

Group type: EXPERIMENTAL
Intervention: Soft tissue ultrasonography
Number of subjects: 31
Study: 8634929

Group type: COMPARATOR
Intervention: Cimetidine 300mg intravenously (i.v.) q6h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heater probe thermocoagulation therapy and cimetidine 300mg i.v. q6h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. qd
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Omeprazole 40mg intravenous bolus initially followed by 40mg i.v. q12h
Number of subjects: 40
Study: 1473431

Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin (20 mg/day for 14 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Standard Piroxicam (20 mg/day for 14 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day for 14 days)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 6439693

Group type: EXPERIMENTAL
Intervention: Glucose alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Glucose plus fat emulsion (3:1 mixture)
Number of subjects: 3
Study: 31220933

Group type: EXPERIMENTAL
Intervention: Child support group (children engaged in supportive behavior 2 days/week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no enrolled child support)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Child support group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 102
Study: 29930520

Group type: EXPERIMENTAL
Intervention: LIFESTYLE psychosocial group intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Brief educational group intervention
Number of subjects: 420
Study: 27348905

Group type: EXPERIMENTAL
Intervention: Comprehensive group (acupoint embedding + forlax)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acupoint embedding group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Forlax group
Number of subjects: 150
Study: 24995756

Group type: EXPERIMENTAL
Intervention: Nicotine replacement pharmacotherapy (6-week regimen)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control group (no nicotine replacement therapy)
Number of subjects: 424
Study: 22828172

Group type: EXPERIMENTAL
Intervention: CBT‐T
Number of subjects: 60

Group type: COMPARATOR
Intervention: Information-only
Number of subjects: 60
Study: 20141732

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese medicine therapy and chemotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Chemotherapy only (control group)
Number of subjects: 95
Study: 17394179

Group type: EXPERIMENTAL
Intervention: anti-tumor necrosis factor alpha (anti-TNFalpha) therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 6-DVU score
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study: 15826418

Group type: EXPERIMENTAL
Intervention: Autologous blood re-infusion units
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vacuum drains
Number of subjects: 50
Study: 12014695

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen (30%/70%)
Number of subjects: 26
Study: 9921385

Group type: EXPERIMENTAL
Intervention: High school driver education courses
Number of subjects: 9

Group type: COMPARATOR
Intervention: Availability of high school driver education courses
Number of subjects: 9
Study: 7784683

Group type: EXPERIMENTAL
Intervention: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous intrathecal anesthesia with 10 mg hyperbaric bupivacaine and 25 mcg fentanyl (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Single intrathecal dose of 15 mg hyperbaric bupivacaine (Group 3)
Number of subjects: 45
Study: 2113756

Group type: EXPERIMENTAL
Intervention: Selegiline (30 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 474476

Group type: EXPERIMENTAL
Intervention: 11.5 mg zinc daily
Number of subjects: 67

Group type: COMPARATOR
Intervention: 14.7 mg zinc daily
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nutrition survey (no specific intervention mentioned)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 67
Study: 31041683

Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone (ET)
Number of subjects: 3746

Group type: COMPARATOR
Intervention: Chemotherapy plus endocrine therapy (ET + C)
Number of subjects: 3746
Study: 28286842

Group type: EXPERIMENTAL
Intervention: Methyl prednisolone (MP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 68
Study: 26417998

Group type: EXPERIMENTAL
Intervention: Ablative fractional Er:YAG laser (AFR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonablative fractional 1550-nm Er:glass laser (NAFR)
Number of subjects: 34
Study: 23359344

Group type: EXPERIMENTAL
Intervention: Tabalumab 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tabalumab 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tabalumab 160 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tabalumab (all doses combined)
Number of subjects: 0
Study: 20888709

Group type: EXPERIMENTAL
Intervention: RT + cisplatin (20 mg/m² weekly)
Number of subjects: 308

Group type: COMPARATOR
Intervention: RT (70 Gy at 1.8-2 Gy/day)
Number of subjects: 308
Study: 19210767

Group type: EXPERIMENTAL
Intervention: Specialized tinnitus care group
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 198
Study: 16551158

Group type: EXPERIMENTAL
Intervention: Youth‐Nominated Support Team‐Version 1 (YST‐1) plus treatment-as-usual
Number of subjects: 289

Group type: COMPARATOR
Intervention: Treatment-as-usual only
Number of subjects: 289
Study: 12657073

Group type: EXPERIMENTAL
Intervention: Home care protocol with preoperative home visits by a nurse and physical therapist, and fewer postoperative visits (9-12 visits)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Existing home care protocol (11-47 visits)
Number of subjects: 136
Study: 10607685

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) therapy
Number of subjects: 54
Study: 9106647

Group type: EXPERIMENTAL
Intervention: Oral etoposide (100 mg given twice daily for 5 days)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Intravenous chemotherapy (cisplatin and etoposide alternating with cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 155

Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 155
Study: 8459986

Group type: EXPERIMENTAL
Intervention: Ondansetron plus dexamethasone (0.15 mg/kg i.v. x 3 and 20 mg i.v.)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Metoclopramide plus dexamethasone (3 mg/kg i.v. x 2 and 20 mg i.v.)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 289
Study: 2429120

Group type: EXPERIMENTAL
Intervention: Lemongrass (abafado)
Number of subjects: 68
Study: 29910012

Group type: EXPERIMENTAL
Intervention: Therapist-rated alliance
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Client-rated alliance
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Task component of alliance
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Task and goal components of alliance
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Therapist alliance
Number of subjects: 123
Study: 27496700

Group type: EXPERIMENTAL
Intervention: Life Goal intervention (Goal Attainment Scaling)
Number of subjects: 66
Study: 24754070

Group type: EXPERIMENTAL
Intervention: Intravenous Idrinol 1000 mg/day for 10-14 days (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic therapy of coronary heart disease (Group 2)
Number of subjects: 60
Study: 22642473

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 300

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 300
Study: 20025892

Group type: EXPERIMENTAL
Intervention: Inhibitory trains of transcranial magnetic stimulation (rTMS) of the right parietal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitory trains of transcranial magnetic stimulation (rTMS) of the left parietal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no rTMS)
Number of subjects: 0
Study: 18449096

Group type: EXPERIMENTAL
Intervention: BPD group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 20
Study: 15651171

Group type: EXPERIMENTAL
Intervention: oblimersen plus dacarbazine
Number of subjects: 14

Group type: COMPARATOR
Intervention: dacarbazine alone
Number of subjects: 14
Study: 9158082

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 15
Study: 7954025

Group type: EXPERIMENTAL
Intervention: rt‐PA
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 115
Study: 3595364

Group type: EXPERIMENTAL
Intervention: Corrugated latex drain
Number of subjects: 60

Group type: COMPARATOR
Intervention: No drain (control)
Number of subjects: 60
Study: 28865098

Group type: EXPERIMENTAL
Intervention: Acotiamide 300 mg/day + rabeprazole 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg/day
Number of subjects: 0
Study: 27982344

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Late open lung strategy (L-OLS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Early open lung strategy (E-OLS)
Number of subjects: 61
Study: 25912391

Group type: EXPERIMENTAL
Intervention: IVUS-guided stent implantation
Number of subjects: 230

Group type: COMPARATOR
Intervention: Angiography-guided stent implantation
Number of subjects: 230
Study: 23688323

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg) administered subcutaneously once weekly for 12 weeks
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once weekly for 12 weeks
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg)
Number of subjects: 104
Study: 20090438

Group type: EXPERIMENTAL
Intervention: 200 mg of intraperitoneal lidocaine
Number of subjects: 370

Group type: COMPARATOR
Intervention: Sterile saline (0.9%)
Number of subjects: 370
Study: 18171451

Group type: EXPERIMENTAL
Intervention: 50% dose + placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: 50% dose
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline (100%) dose
Number of subjects: 26
Study: 16606810

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (OG group)
Number of subjects: 4081

Group type: COMPARATOR
Intervention: Placebo (OP group)
Number of subjects: 4081
Study: 14613506

Group type: EXPERIMENTAL
Intervention: Glutamine-rich protein formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free glutamine formula
Number of subjects: 0
Study: 10908209

Group type: EXPERIMENTAL
Intervention: Aspirin plus coumarins
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 1058
Study: 8757358

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of gentamicin or tobramycin (4 mg/kg IV)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pharmacokinetic dosing (initial dose of 2 mg/kg IV every 12 hours)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Once-daily dosing and pharmacokinetic dosing of aminoglycosides
Number of subjects: 96
Study: 1434581

Group type: EXPERIMENTAL
Intervention: Aerobic dance program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Walk-jog program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 60
Study: 3931448

Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 133
Study: 31228505

Group type: EXPERIMENTAL
Intervention: Vegetable Maths Masters app
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control app (similar but did not include any foods)
Number of subjects: 74
Study: 29913254

Group type: EXPERIMENTAL
Intervention: 5 fractions (7.25 Gy in 2 weeks)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: 12 fractions (4.3 Gy in 2.5 weeks)
Number of subjects: 255
Study: 27106890

Group type: EXPERIMENTAL
Intervention: Phase 3 clinical trials
Number of subjects: 29
Study: 25195982

Group type: EXPERIMENTAL
Intervention: DART (Dispatcher-Assisted Randomized Trial)
Number of subjects: 8626
Study: 22301472

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 100

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 100
Study: 20228513

Group type: EXPERIMENTAL
Intervention: Theophylline (either orally or intravenously) with hydration using sodium bicarbonate
Number of subjects: 280

Group type: COMPARATOR
Intervention: Hydration with sodium bicarbonate only
Number of subjects: 280
Study: 17429316

Group type: EXPERIMENTAL
Intervention: Perphenazine (0.1 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15117142

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Amikacin, Ofloxacin, Gentamycin
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cloxacillin, Ofloxacin, Erythromycin, Ciprofloxacin, Gentamicin, Tetracycline
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 250
Study: 11561215

Group type: EXPERIMENTAL
Intervention: Ingestion of 50% sunflower oil (1.5 g/kg) followed by FSIVGTT 4 h later (test 2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ingestion of 50% sunflower oil (1.5 g/kg) with i.v. addition of 100 U/kg heparin prior to FSIVGTT (test 3)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (test 1: FSIVGTT, 0.3 g/kg glucose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ingestion of sunflower oil triglyceride emulsion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Heparin-induced high levels of FFA (test 3)
Number of subjects: 17
Study: 9743819

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 800 mg per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS)
Number of subjects: 42
Study: 7945623

Group type: EXPERIMENTAL
Intervention: Severe antepartum preeclampsia and eclamptic seizures after cesarean section and subtotal hysterectomy
Number of subjects: 1
Study: 3174030

Group type: EXPERIMENTAL
Intervention: Iodine‐125 plaque irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0
Study: 28691363

Group type: EXPERIMENTAL
Intervention: Glaucoma Australia educational intervention (telephone-based counselling and mail-out information)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (usual care and information from treating ophthalmologist)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Glaucoma Australia educational intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 26520169

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 2.0 mg ranibizumab
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VMA+ group
Number of subjects: 124
Study: 25601227

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Olixia pure(®) ; Croma Pharma, Korneuburg, Austria) eye drops
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physiologic saline solution (placebo control)
Number of subjects: 16
Study: 23664526

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 181

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 181
Study: 21040582

Group type: EXPERIMENTAL
Intervention: Ambrotose AO® (4 capsules per day = 2 grams per day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ambrotose AO®
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 18706769

Group type: EXPERIMENTAL
Intervention: Nicotine medications
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 16357350

Group type: EXPERIMENTAL
Intervention: PDA-based clinical decision support system (CDSS) for NSAID prescribing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CDSS)
Number of subjects: 0
Study: 14618061

Group type: EXPERIMENTAL
Intervention: Rate Smoothing (RS) On
Number of subjects: 219

Group type: COMPARATOR
Intervention: Rate Smoothing (RS) Off
Number of subjects: 219
Study: 15055252

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 117

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 117
Study: 10029122

Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning and home follow‐up protocol by advanced practice nurses
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 363
Study: 8616475

Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 estimation by immunoenzymatic assay (Enzymun Cyfra 21-1) in lung cancer patients
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (benign lung diseases)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 estimation in advanced lung cancer stages
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cytokeratin-19 estimation in small cell lung cancer
Number of subjects: 153
Study: 2183804

Group type: EXPERIMENTAL
Intervention: Auranofin (0.15-0.20 mg/kg/day)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Auranofin and Placebo
Number of subjects: 231
Study: 7307563

Group type: EXPERIMENTAL
Intervention: Triple gel (sequential application of Keralyt, Estar, and Topsyn gels)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 percent salicylic acid in Sofsyn oil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 percent salicylic acid in mineral oil
Number of subjects: 30
Study: 31741068

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral serratus plane block with 0.25% bupivacaine 30 ml each side
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received bilateral ultrasound-guided 2 ml 0.9% saline subcutaneously each block side
Number of subjects: 40
Study: 28143456

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg in combination with metformin 1000 mg BID
Number of subjects: 30

Group type: COMPARATOR
Intervention: Liraglutide 3 mg QD alone
Number of subjects: 30
Study: 25590472

Group type: EXPERIMENTAL
Intervention: Internal intradermal suturing
Number of subjects: 0

Group type: COMPARATOR
Intervention: External intradermal suturing
Number of subjects: 0
Study: 24215592

Group type: EXPERIMENTAL
Intervention: Alternate day fasting (ADF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 21455122

Group type: EXPERIMENTAL
Intervention: Active treatment (multicomponent lifestyle intervention)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Weight loss/maintenance group (n = 154)
Number of subjects: 507
Study: 19723864

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 113
Study: 17766602

Group type: EXPERIMENTAL
Intervention: In situ uterine repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: Exteriorized uterine repair
Number of subjects: 80